FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171661657> ?p ?o ?g. }

• W2171661657 abstract "HomeStrokeVol. 39, No. 8Response to Letter by Paraskevas Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBResponse to Letter by Paraskevas Hiroharu Kataoka, MD, PhD Hiroharu KataokaHiroharu Kataoka Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan Search for more papers by this author Originally published3 Jul 2008https://doi.org/10.1161/STROKEAHA.107.522011Stroke. 2008;39:e135Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: July 3, 2008: Previous Version 1 Response:We have recently demonstrated that simvastatin suppresses the progression of experimentally induced rat cerebral aneurysms (CA). Stains are used in the prevention and treatment of various cardiovascular and cerebrovascular diseases. Large clinical trials demonstrated the efficacy of statins in preventing cardiovascular and cerebrovascular events,1–4 whereas there are no randomized controlled trials proving statins’ beneficial effects on aortic abdominal aneurysm and CA so far.A clinical trial investigating the preventive effect on CA rupture is difficult because of a low incidence of CA rupture. Only <1% of unruptured CA lead to subarachnoid hemorrhage in 1 year.5 If CA rupture would be set as a primary end point, a tremendous number of patients would need to be enrolled in a study. Such a clinical trial encompasses an ethical problem. Subarachnoid hemorrhage has a high mortality, and surgical clipping and endovascular coiling can prevent CA rupture. To overcome the difficulties described above, we must identify a predictive factor for the stability of CA walls.Positive results obtained from an animal experiment cannot be directly applied to human disease. However, a series of our studies using an experimentally induced CA model provide evidences that vascular inflammation and resultant endothelial dysfunction contribute to degenerative changes in CA walls.6,7 We hope our results will be a clue to the development of a less invasive treatment for preventing subarachoid hemorrhage.DisclosuresNone.1 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360: 7–22.CrossrefMedlineGoogle Scholar2 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383–1389.MedlineGoogle Scholar3 The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339: 1349–1357.CrossrefMedlineGoogle Scholar4 Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E; Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335: 1001–1009.CrossrefMedlineGoogle Scholar5 International Study of Unruptured Intracranial Aneurysms Investigators. Unruptured intracranial aneurysms–risk of rupture and risks of surgical intervention. N Engl J Med. 1998; 339: 1725–1733.CrossrefMedlineGoogle Scholar6 Aoki T, Kataoka H, Morimoto M, Nozaki K, Hashimoto N. Macrophage-derived matrix metalloproteinase-2 and -9 promote the progression of cerebral aneurysms in rats. Stroke. 2007; 38: 162–169.LinkGoogle Scholar7 Aoki T, Kataoka H, Shimamura M, Nakagami H, Wakayama K, Moriwaki T, Ishibashi R, Nozaki K, Morishita R, Hashimoto N. NF-kappaB is a key mediator of cerebral aneurysm formation. Circulation. 2007; 116: 2830–2840.LinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails August 2008Vol 39, Issue 8 Advertisement Article InformationMetrics https://doi.org/10.1161/STROKEAHA.107.522011 Originally publishedJuly 3, 2008 PDF download Advertisement" @default.
• W2171661657 created "2016-06-24" @default.
• W2171661657 creator A5080713878 @default.
• W2171661657 date "2008-08-01" @default.
• W2171661657 modified "2023-10-18" @default.
• W2171661657 title "Response to Letter by Paraskevas" @default.
• W2171661657 cites W1979745959 @default.
• W2171661657 cites W2063887943 @default.
• W2171661657 cites W2322095705 @default.
• W2171661657 cites W3145965715 @default.
• W2171661657 cites W38523360 @default.
• W2171661657 cites W424467158 @default.
• W2171661657 doi "https://doi.org/10.1161/strokeaha.107.522011" @default.
• W2171661657 hasPublicationYear "2008" @default.
• W2171661657 type Work @default.
• W2171661657 sameAs 2171661657 @default.
• W2171661657 citedByCount "0" @default.
• W2171661657 crossrefType "journal-article" @default.
• W2171661657 hasAuthorship W2171661657A5080713878 @default.
• W2171661657 hasConcept C126322002 @default.
• W2171661657 hasConcept C12770488 @default.
• W2171661657 hasConcept C138885662 @default.
• W2171661657 hasConcept C141071460 @default.
• W2171661657 hasConcept C164705383 @default.
• W2171661657 hasConcept C168563851 @default.
• W2171661657 hasConcept C2776098176 @default.
• W2171661657 hasConcept C2776848632 @default.
• W2171661657 hasConcept C2777736543 @default.
• W2171661657 hasConcept C41895202 @default.
• W2171661657 hasConcept C535046627 @default.
• W2171661657 hasConcept C71924100 @default.
• W2171661657 hasConceptScore W2171661657C126322002 @default.
• W2171661657 hasConceptScore W2171661657C12770488 @default.
• W2171661657 hasConceptScore W2171661657C138885662 @default.
• W2171661657 hasConceptScore W2171661657C141071460 @default.
• W2171661657 hasConceptScore W2171661657C164705383 @default.
• W2171661657 hasConceptScore W2171661657C168563851 @default.
• W2171661657 hasConceptScore W2171661657C2776098176 @default.
• W2171661657 hasConceptScore W2171661657C2776848632 @default.
• W2171661657 hasConceptScore W2171661657C2777736543 @default.
• W2171661657 hasConceptScore W2171661657C41895202 @default.
• W2171661657 hasConceptScore W2171661657C535046627 @default.
• W2171661657 hasConceptScore W2171661657C71924100 @default.
• W2171661657 hasIssue "8" @default.
• W2171661657 hasLocation W21716616571 @default.
• W2171661657 hasOpenAccess W2171661657 @default.
• W2171661657 hasPrimaryLocation W21716616571 @default.
• W2171661657 hasRelatedWork W2019788863 @default.
• W2171661657 hasRelatedWork W2047500592 @default.
• W2171661657 hasRelatedWork W2081408875 @default.
• W2171661657 hasRelatedWork W2089211548 @default.
• W2171661657 hasRelatedWork W2123168171 @default.
• W2171661657 hasRelatedWork W2133820966 @default.
• W2171661657 hasRelatedWork W2567842392 @default.
• W2171661657 hasRelatedWork W2737184613 @default.
• W2171661657 hasRelatedWork W2948260067 @default.
• W2171661657 hasRelatedWork W3030763831 @default.
• W2171661657 hasVolume "39" @default.
• W2171661657 isParatext "false" @default.
• W2171661657 isRetracted "false" @default.
• W2171661657 magId "2171661657" @default.
• W2171661657 workType "article" @default.